Sunshine Biopharma Inc. Business Acquisition, Pro Forma Net Income (Loss)
Sunshine Biopharma Inc. (SBFM) reported Business Acquisition, Pro Forma Net Income (Loss) of -$26.16 million for the 12-month period ending 2022-12-31, per its 10-Q filed 2023-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2023-11-13
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2022-12-31 | -$26.16M 10-Q · filed 2023-11-13 |
| 2021-12-31 | -$12.29M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |